Azwidihwi Takalani

University of the Witwatersrand — South Africa

Medicine · Health Sciences

9h-index445citations29works3.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

SARS-CoV-2 and COVID-19 Research(17), Vaccine Coverage and Hesitancy(15), COVID-19 Clinical Research Studies(7), HIV Research and Treatment(6), Heparin-Induced Thrombocytopenia and Thrombosis(6)

Publications28 total

Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIV
UNC Libraries·2025Open Access
Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIV
Nature Communications·2025· 1 citedOpen Access
Africa is an Essential Partner in the Research and Development of an HIVVaccine
Current HIV Research·2025
Pregnancy and contraceptive use among participants of childbearing potential in the HVTN 705 HIV vaccine trial in Southern Africa
Frontiers in Reproductive Health·2025Open Access
Analytical treatment interruption among women with HIV in southern Africa who received VRC01 or placebo in the Antibody Mediated Prevention Study: ATI stakeholder engagement, implementation and early clinical data
Journal of the International AIDS Society·2025· 2 citedOpen Access
Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 randomised trial
The Lancet HIV·2025· 3 cited
Hybrid versus vaccine immunity of mRNA-1273 among people living with HIV in East and Southern Africa: a prospective cohort analysis from the multicentre CoVPN 3008 (Ubuntu) study
UNC Libraries·2025Open Access
Hybrid versus vaccine immunity of mRNA-1273 among people living with HIV in East and Southern Africa: a prospective cohort analysis from the multicentre CoVPN 3008 (Ubuntu) study
EClinicalMedicine·2025· 5 citedOpen Access
Safety, Pharmacokinetics, and Neutralization Activity of PGDM1400LS, VRC07-523-LS, and PGT121.414.LS Infused Intravenously or Subcutaneously: A Phase 1 Randomized Trial (HVTN 140/HPTN 101 Part B)
SSRN Electronic Journal·2025Open Access
Safety, effectiveness and immunogenicity of heterologous mRNA-1273 boost after prime with Ad26.COV2.S among healthcare workers in South Africa: The single-arm, open-label, phase 3 SHERPA study
PLOS Global Public Health·2024· 3 citedOpen Access
Vaccine pharmacovigilance in South Africa: successes and limitations of current approaches
Expert Opinion on Drug Safety·2024· 5 cited
Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial
The Lancet Infectious Diseases·2024· 29 citedOpen Access
Safety, Effectiveness and Immunogenicity of heterologous mRNA-1273 Boost after Prime with Ad26.COV2.S among Healthcare Workers in South Africa: the single-arm, open-label, Phase 3 SHERPA Study
2024· 1 citedOpen Access
Allergic reactions to the Ad26.COV2.S Vaccine in South Africa
2024Open Access
Safety of a second homologous Ad26.COV2.S vaccine among healthcare workers in the phase 3b implementation Sisonke study in South Africa
Vaccine·2024· 3 citedOpen Access
Hybrid Versus Vaccine Immunity of mRNA-1273 Among People Living with HIV in East and Southern Africa: The Multicentre, Open-Label COVPN 3008 (Ubuntu) Clinical Trial
SSRN Electronic Journal·2024Open Access
Post-COVID symptom profiles and duration in a global convalescent COVID-19 observational cohort: Correlations with demographics, medical history, acute COVID-19 severity and global region
Journal of Global Health·2023· 18 citedOpen Access
Vascular thrombosis after single dose Ad26.COV2.S vaccine in healthcare workers in South Africa: open label, single arm, phase 3B study (Sisonke study)
BMJ Medicine·2023· 5 citedOpen Access
Breakthrough SARS-CoV-2 infections during periods of delta and omicron predominance, South Africa
The Lancet·2022· 48 citedOpen Access
Safety evaluation of the single-dose Ad26.COV2.S vaccine among healthcare workers in the Sisonke study in South Africa: A phase 3b implementation trial
PLoS Medicine·2022· 20 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Nigel Garrett(23), Linda‐Gail Bekker(23), Glenda Gray(22), Ameena Goga(15), Ishen Seocharan(12), Lawrence Corey(12), Ian Sanne(11), Simbarashe Takuva(11), William Brumskine(10), Tarylee Reddy(10), Katherine Gill(9), Craig Innes(9), Jonny Peter(9), Jackline Odhiambo(9), Margaret Yacovone(8), Yunda Huang(8), Sharlaa Badal‐Faesen(8), Kathryn Mngadi(8), Maphoshane Nchabeleng(8), Vernon Louw(8)